Generic Name: abiraterone

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Janssen

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Zytiga is a CYP17 inhibitor approved for metastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant) and for high-risk castration-sensitive prostate cancer.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Medical or surgical castration reduces testosterone levels, but other cells in the body can still make androgens. Zytiga blocks an enzyme called CYP17 needed for androgen production. It should be used with GnRH agonists to stop testosterone production.

Studies showed that Zytiga delays disease progression and improves survival of men with metastatic castration-resistant prostate cancer. The LATITUTDE trial showed that adding Zytiga to GnRH agonists slows progression and improves survival of men with high-risk metastatic castration-sensitive prostate cancer.


Dosing Info: Zytiga is pill taken with prednisone once daily on an empty stomach.

Side Effects

Common side effects include fatigue, joint pain, nausea, diarrhea, headache, hot flashes, swelling and high blood pressure. Potential serious side effects include elevated potassium, hormone imbalances and liver toxicity.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 19, 2018